Talk:Erdheim–Chester disease

Quote or paraphrase to avoid plagiarism
Since the text of the lead is almost identical to the cited reference at http://www.diseasesdatabase.com/umlsdef.asp?glngUserChoice=29792, should this be explicitly quoted in the article? Otherwise, it might be best to rephrase the lead. zadignose (talk) 14:20, 28 April 2008 (UTC)

Two months later, I've explicitly made this a quote, and gone to the source it was lifted from. Rewrite it, preferably in less abstruse language, if you want to remove the explicit citation. zadignose (talk) 15:05, 18 June 2008 (UTC)

P.S. Also note that this text could likely be deleted if it can not be paraphrased, or a Free-Documentation-License can not be provided. zadignose (talk) 15:07, 18 June 2008 (UTC)

Reword
This article uses 'involvement' without being specific. Examples should be given and the article reworded. — Preceding unsigned comment added by 78.149.44.134 (talk) 17:25, 20 August 2011 (UTC)

Guideline
10.1182/blood-2014-03-561381 JFW &#124; T@lk  10:37, 27 July 2014 (UTC)

Updating a sentence
This line "Approximately 500 cases have been reported in the literature to date.[17]" can be edited to include a new source article, Erdheim-Chester Disease: a Concise Review, from 2019 that claims there are 1500 reported cases worldwide. 192.44.242.208 (talk) 13:42, 2 March 2022 (UTC)

Prognosis
There is a call for a Reference in this section. I don't know enough about Wikipedia to add this, but a believe a relevant reference is:

Journal of Clinical Oncology > List of Issues > Volume 38, Issue 15_suppl > Meeting Abstract | 2020 ASCO Annual Meeting I

HEMATOLOGIC MALIGNANCIES—LEUKEMIA, MYELODYSPLASTIC SYNDROMES, AND ALLOTRANSPLANT Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2020.38.15_suppl.7560 Journal of Clinical Oncology - published online before print May 25, 2020

Long-term outcome of 117 patients with Erdheim-Chester disease and mixed histiocytosis receiving targeted therapies (BRAF and MEK inhibitors): A monocentric experience. — Preceding unsigned comment added by 80.193.244.222 (talk) 15:14, 24 March 2022 (UTC)